Loading stock data…
Entrada Therapeutics, Inc. (TRDA)
$7.71-0.03 (-0.39%)
After Hours$7.71+0.00 (+0.00%)· Last close Jun 29
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Entrada Therapeutics, Inc. in the Healthcare sector is trading at $7.71 with a market capitalization of $274M. Wall Street consensus targets $18.75 (4 analysts), implying a +143.2% move over the next 12 months. The stock is currently 53% below its 52-week high of $16.45, remaining 18.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 72 is overbought against a weak tape. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +143.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 72 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $875,000↓ | $1.30M↓ | $1.61M↓ | $1.95M↓ | $20.56M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$42.30M↓ | -$42.21M↑ | -$47.05M↓ | -$46.85M↓ | -$21.79M |
| Net Income | -$39.72M↓ | -$39.16M↑ | -$44.13M↓ | -$43.10M↓ | -$17.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$274.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.39%
Volume
Today's trading volume
236,768
Recent News
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory patients with Duchenne muscular dystrophy, or DMD, who have mutations amenable to exon 44 skipping
Entrada’s stock drops as DMD drug’s efficacy falls short
At a 6 mg/kg dose, ENTR-601-44 didn’t elevate dystrophin levels to analyst expectations, or to the baseline change recorded by Novartis’ del-zota.
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?
Sarepta stock toppled Thursday as investors digested the better-than-feared sales of its beleaguered gene therapy, Elevidys.
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6%
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +10.59% and -86.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?